Clearmind completes enrollment for Part C of CMND-100 Phase I/IIa trial
Clearmind Medicine announced that patient enrollment was completed for Part C of its CMND-100 Phase I/IIa clinical trial. Part C is a randomized, double-blind, placebo-controlled multiple-dose study evaluating safety, tolerability and pharmacokinetics at sites in the United States and Israel. The announcement did not include financial results or guidance.
Read source-backed brief